TGF-beta-induced Myelin Peptide-specific Regulatory T Cells Mediate Antigen-specific Suppression of Induction of Experimental Autoimmune Encephalomyelitis
Overview
Affiliations
The low number of natural regulatory T cells (nTregs) in the circulation specific for a particular Ag and concerns about the bystander suppressive capacity of expanded nTregs presents a major clinical challenge for nTreg-based therapeutic treatment of autoimmune diseases. In the current study, we demonstrate that naive CD4+CD25-Foxp3- T cells specific for the myelin proteolipid protein (PLP)139-151 peptide can be converted into CD25+Foxp3+ induced Treg cells (iTregs) when stimulated in the presence of TGF-beta, retinoic acid, and IL-2. These PLP139-151-specific iTregs (139-iTregs) have a phenotype similar to nTregs, but additionally express an intermediate level of CD62L and a high level of CD103. Upon transfer into SJL/J mice, 139-iTregs undergo Ag-driven proliferation and are effective at suppressing induction of experimental autoimmune encephalomyelitis induced by the cognate PLP139-151 peptide, but not PLP178-191 or a mixture of the two peptides. Furthermore, 139-iTregs inhibit delayed-type hypersensitivity responses to PLP139-151, but not PLP178-191, myelin oligodendrocyte glycoprotein (MOG)35-55, or OVA323-339 in mice primed with a mixture of PLP139-151 and the other respective peptides. Additionally, 139-iTregs suppress the proliferation and activation of PLP139-151-, but not MOG35-55-specific CD4+ T cells in SJL/B6 F1 mice primed with a combination of PLP139-151 and MOG35-55. These findings suggest that Ag-specific iTregs are amplified in vivo when exposed to cognate Ag under inflammatory conditions, and these activated iTregs suppress CD4+ responder T cells in an Ag-specific manner.
Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis.
Greco G, Sarpietro M Molecules. 2024; 29(19).
PMID: 39407617 PMC: 11477494. DOI: 10.3390/molecules29194689.
Arellano G, Acuna E, Loda E, Moore L, Tichauer J, Castillo C J Neuroinflammation. 2024; 21(1):144.
PMID: 38822334 PMC: 11143617. DOI: 10.1186/s12974-024-03126-3.
Regulating the regulatory T cells as cell therapies in autoimmunity and cancer.
Hosseinalizadeh H, Rabiee F, Eghbalifard N, Rajabi H, Klionsky D, Rezaee A Front Med (Lausanne). 2023; 10:1244298.
PMID: 37828948 PMC: 10565010. DOI: 10.3389/fmed.2023.1244298.
Podojil J, Genardi S, Chiang M, Kakade S, Neef T, Murthy T J Immunol. 2022; 209(3):465-475.
PMID: 35725270 PMC: 9339508. DOI: 10.4049/jimmunol.2200208.
Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy.
Huppert L, Green M, Kim L, Chow C, Leyfman Y, Daud A Cell Mol Immunol. 2021; 19(1):33-45.
PMID: 34417572 PMC: 8752797. DOI: 10.1038/s41423-021-00742-4.